Volitionrx Net Income From Continuing Ops from 2010 to 2025

VNRX Stock  USD 0.63  0.01  1.56%   
Volitionrx Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2025. During the period from 2010 to 2025, Volitionrx Net Loss regression line of annual values had r-squared of  0.92 and arithmetic mean of (16,748,811). View All Fundamentals
 
Net Loss  
First Reported
2011-03-31
Previous Quarter
-7.1 M
Current Value
-5.9 M
Quarterly Volatility
3.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Volitionrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Volitionrx's main balance sheet or income statement drivers, such as Interest Expense of 267.6 K, Other Operating Expenses of 44.4 M or Total Operating Expenses of 44.4 M, as well as many indicators such as Price To Sales Ratio of 71.97, Dividend Yield of 0.0 or Days Sales Outstanding of 122. Volitionrx financial statements analysis is a perfect complement when working with Volitionrx Valuation or Volatility modules.
  
Check out the analysis of Volitionrx Correlation against competitors.
For more information on how to buy Volitionrx Stock please use our How to Invest in Volitionrx guide.

Latest Volitionrx's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Volitionrx over the last few years. It is Volitionrx's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Volitionrx's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Volitionrx Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(16,748,811)
Geometric Mean13,019,975
Coefficient Of Variation(65.29)
Mean Deviation9,274,307
Median(14,769,207)
Standard Deviation10,935,634
Sample Variance119.6T
Range29.6M
R-Value(0.96)
Mean Square Error10.1T
R-Squared0.92
Slope(2,204,921)
Total Sum of Squares1793.8T

Volitionrx Net Income From Continuing Ops History

2025-29.3 M
2024-30.8 M
2023-34.2 M
2022-31.8 M
2021-27 M
2020-20.4 M
2019-16.1 M

About Volitionrx Financial Statements

Volitionrx investors use historical fundamental indicators, such as Volitionrx's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Volitionrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-30.8 M-29.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Volitionrx Stock Analysis

When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.